Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
hUC-MSCs, β-NGF, and Postoperative Cognition
2026-08-25
This study identifies a β-NGF-dependent STMN2/NMNAT2–SARM1–NF-κB mechanism through which human umbilical cord mesenchymal stem cells improve cognitive impairment after tibial fracture surgery in aged mice. Its combination of behavioral, pathological, proteomic, and pathway-perturbation data provides a mechanistic framework for studying cell-based treatment of perioperative neurocognitive disorders.
-
Wnt–O-GlcNAcylation Rewires Glycolysis in Bone
2026-08-25
The reference study identifies O-GlcNAcylation as a metabolic and post-translational mechanism that enables Wnt3a-driven osteoblastogenesis. Its evidence connects Wnt signaling to PDK1 stabilization, aerobic glycolysis, bone formation, and fracture healing, providing a framework for dissecting anabolic Wnt biology.
-
Sunitinib Workflows for RCC and Angiogenesis
2026-08-24
Sunitinib supports more than simple viability testing: its multi-target RTK profile enables coordinated studies of angiogenesis, apoptosis, cell-cycle control, and treatment resistance. This workflow translates recent ferroptosis findings into practical renal cell carcinoma assays and combination-testing strategies.
-
Clarithromycin CYP3A Inhibitor Workflow Guide
2026-08-24
Build reproducible CYP3A inhibition assays for drug-drug interaction research, statin metabolism interaction studies, and pharmacokinetic studies. This guide combines practical formulation advice with a CYP-independent comparison strategy informed by the dabigatran reference study.
-
Sex Differences in Angiotensin II Hypertension
2026-08-22
Xue, Pamidimukkala, and Hay used telemetry in conscious mice to show that chronic angiotensin II produces a substantially larger pressor response in males than females. Gonadectomy, baroreflex testing, and ganglionic blockade further implicated sex hormone status and sympathetic regulation, providing a useful framework for sex-aware hypertension experiments.
-
Starvation, ER Ca2+, and Cell Fate in Bombyx mori
2026-08-22
A 2026 study in Bombyx mori identifies an ER-Ca2+-calpain signaling axis that governs the shift from protective autophagy to apoptosis during prolonged starvation. Its time-resolved measurements and 2-APB intervention connect energy depletion, calcium-store dysregulation, ATG5 cleavage, and caspase-3 activation, while also highlighting limits on interpreting pharmacological inhibition as pathway-specific evidence.
-
GKT137831: Redox Control Beyond ROS Scavenging
2026-08-21
GKT137831 is a dual NADPH oxidase Nox1/Nox4 inhibitor for testing how compartmentalized oxidant signaling shapes vascular remodeling, fibrosis, and ferroptosis vulnerability. This thought-leadership analysis connects Nox biology with plasma-membrane lipid remodeling while separating validated evidence from translational hypotheses.
-
How SAL Protects Endothelial Cells Through EZH2
2026-08-20
The reference study identifies EZH2 as a mechanistic link between salidroside-mediated protection and the regulation of inflammation and autophagy in H2O2-stressed HUVECs. Its combination of functional, molecular, computational, and gene-silencing experiments supports a testable model for endothelial protection while also highlighting the limits of an in vitro oxidative-stress system.
-
KPT-330 (Selinexor) for CRM1 Research
2026-08-20
KPT-330 (Selinexor) converts CRM1 inhibition into measurable nuclear-retention, viability, apoptosis, and combination-therapy readouts. This workflow highlights how to test platinum sensitization in DLBCL while retaining practical options for NSCLC, RCC, and xenograft research.
-
Affinity-Purified Goat Anti-Rabbit IgG (H+L) Guide
2026-08-19
Build sensitive Western blot, ELISA, IHC, and ICC workflows around an affinity-purified HRP secondary that recognizes rabbit IgG heavy and light chains. This practical guide connects assay design and troubleshooting to the ERα/KRT19 findings reported in papillary thyroid carcinoma research.
-
NSP15 Inhibitor Screening Reveals Thymopentin and Oleuropein
2026-08-19
The reference study used structure-based virtual screening and molecular dynamics to identify thymopentin and oleuropein as high-priority natural-product binders of SARS-CoV-2 NSP15. Its main contribution is a computationally supported hypothesis for suppressing an immune-evasion enzyme, while biochemical, cellular, and clinical validation remain necessary.
-
Sunitinib and the Next Frontier in RCC Translation
2026-08-18
Sunitinib is more than an anti-angiogenic tool: its multi-target RTK activity creates a platform for studying tumor dependence, adaptive resistance, and ferroptosis in clear cell renal cell carcinoma. This thought-leadership guide connects mechanism to experimental design, highlights TRIB3-SLC7A11/GPX4 biology, and offers a translational framework for using Sunitinib in resistance-focused research.
-
Deferoxamine Mesylate in Ferroptosis Assays
2026-08-18
Deferoxamine mesylate gives researchers a controllable way to alter labile iron while separating iron availability from plasma-membrane repair mechanisms in ferroptosis. This workflow connects ferroptosis, HIF-1α stabilization, oxidative stress protection, cancer biology, and tissue-repair assays with practical dosing, controls, and troubleshooting guidance.
-
TMEM16F, Ferroptosis, and Immune Rejection
2026-08-17
Yang et al. identify TMEM16F-mediated phospholipid scrambling as a terminal anti-ferroptotic response that limits plasma-membrane damage after lipid peroxide accumulation. Blocking this response increases lytic death, danger-signal release, tumor control, and the response to PD-1 blockade, revealing a membrane-biophysical route to tumor immune rejection.
-
GKT137831: Redox Control at the Cell Membrane
2026-08-17
GKT137831, a dual NADPH oxidase Nox1/Nox4 inhibitor, offers a precise way to separate upstream ROS generation from terminal plasma-membrane failure. This article connects vascular redox biology with ferroptosis assay design while defining practical controls, limitations, and research applications.